Market Overview

Royalty Pharma Announces Acceptance Levels of its Further Increased Offer for Elan Corporation

In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels of its Further Increased Offer for Elan Corporation, plc (NYSE: ELN).

Background

On 2 May 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc ("Elan") (the "Original Offer").

On 20 May 2013, Royalty Pharma announced the terms of a revision to the Original Offer (the "Increased Offer"). The Increased Offer was made on 23 May 2013 and was an all cash offer of US$12.50 per Elan Share (including each Elan Share represented by an Elan ADS). The full terms of, and conditions to, the Increased Offer and the procedure for acceptance were set out in the revised offer document despatched by Royalty Pharma on 23 May 2013 (the "Revised Offer Document").  The initial closing date for the Increased Offer, as set out in the Revised Offer Document, was 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on 6 June 2013 (unless extended).

On 6 June 2013,

See full press release

Posted-In: News Guidance Contracts Asset Sales Management M&A Global

 

Related Articles (ELN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters